[
  {
    "ts": null,
    "headline": "1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell",
    "summary": "Vertex stock has climbed more than 60% over three years.",
    "url": "https://finnhub.io/api/news?id=f0c44153a74d908cd400e7d9d69d1d8fd269dab5de285eb9c807f9085a6a9cad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770748500,
      "headline": "1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell",
      "id": 139034971,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex stock has climbed more than 60% over three years.",
      "url": "https://finnhub.io/api/news?id=f0c44153a74d908cd400e7d9d69d1d8fd269dab5de285eb9c807f9085a6a9cad"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals at Turning Point Ahead of Phase 3 Kidney Drug Data, RBC Says",
    "summary": "Vertex Pharmaceuticals (VRTX) is at a critical turning point with its lead kidney drug, povetacicept",
    "url": "https://finnhub.io/api/news?id=dd74b71163321ebae35a81259dcd641899e73ca91916928734e719a0a5be2490",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770741955,
      "headline": "Vertex Pharmaceuticals at Turning Point Ahead of Phase 3 Kidney Drug Data, RBC Says",
      "id": 139033566,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) is at a critical turning point with its lead kidney drug, povetacicept",
      "url": "https://finnhub.io/api/news?id=dd74b71163321ebae35a81259dcd641899e73ca91916928734e719a0a5be2490"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards?",
    "summary": "VRTX is set to report Q4 results amid strong Trikafta demand. Alyftrek launches are gaining traction while investors are eyeing Casgevy and Journavx sales.",
    "url": "https://finnhub.io/api/news?id=d4af89dea46cf3b9e8a0210c058140b2b6d334f2e01b36272bf2bd2ee670bcab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770738300,
      "headline": "Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards?",
      "id": 139033567,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "VRTX is set to report Q4 results amid strong Trikafta demand. Alyftrek launches are gaining traction while investors are eyeing Casgevy and Journavx sales.",
      "url": "https://finnhub.io/api/news?id=d4af89dea46cf3b9e8a0210c058140b2b6d334f2e01b36272bf2bd2ee670bcab"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy Vertex Before Feb. 12?",
    "summary": "Biotech Vertex, known for its cystic fibrosis therapies, is set to report earnings on Feb. 12",
    "url": "https://finnhub.io/api/news?id=bd0f7159e0c581a47b90255efb013bac84b3b2a04ae2866adb5acd04a4a0b91d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770735300,
      "headline": "Should You Buy Vertex Before Feb. 12?",
      "id": 139032007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Biotech Vertex, known for its cystic fibrosis therapies, is set to report earnings on Feb. 12",
      "url": "https://finnhub.io/api/news?id=bd0f7159e0c581a47b90255efb013bac84b3b2a04ae2866adb5acd04a4a0b91d"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Partners With WuXi To Broaden Autoimmune Pipeline Beyond Cystic Fibrosis",
    "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) entered an agreement with WuXi Biologics to co-develop a trispecific T-cell Engager for B-cell mediated autoimmune diseases. The collaboration focuses on bringing a new class of T-cell based therapies into Vertex's pipeline beyond its established cystic fibrosis franchise. For you as an investor, this move highlights how Vertex is looking to build on its position in cystic fibrosis by adding a new approach in autoimmune diseases. T-cell Engagers are an...",
    "url": "https://finnhub.io/api/news?id=89f24ffeb70cd3e947e9019cc707b4dae7252665cb1e8aef363e01c218a51437",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770721669,
      "headline": "Vertex Partners With WuXi To Broaden Autoimmune Pipeline Beyond Cystic Fibrosis",
      "id": 139028446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) entered an agreement with WuXi Biologics to co-develop a trispecific T-cell Engager for B-cell mediated autoimmune diseases. The collaboration focuses on bringing a new class of T-cell based therapies into Vertex's pipeline beyond its established cystic fibrosis franchise. For you as an investor, this move highlights how Vertex is looking to build on its position in cystic fibrosis by adding a new approach in autoimmune diseases. T-cell Engagers are an...",
      "url": "https://finnhub.io/api/news?id=89f24ffeb70cd3e947e9019cc707b4dae7252665cb1e8aef363e01c218a51437"
    }
  },
  {
    "ts": null,
    "headline": "A Look At Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Momentum",
    "summary": "Event context and recent share performance Vertex Pharmaceuticals (VRTX) has recently drawn investor attention without a single clear news catalyst, as the stock shows a month return of about 1.5% and a past 3 months return near 9.7%. See our latest analysis for Vertex Pharmaceuticals. At a share price of US$470.87, Vertex’s recent 90 day share price return of 9.7% sits alongside a relatively flat 1 year total shareholder return of 0.19%. This hints that momentum has picked up more recently...",
    "url": "https://finnhub.io/api/news?id=12d5f730e508eba4a1ffa2d8756da0dba64c423e6a3f9e4e842dc629a5459e7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770703613,
      "headline": "A Look At Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Momentum",
      "id": 139027165,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Event context and recent share performance Vertex Pharmaceuticals (VRTX) has recently drawn investor attention without a single clear news catalyst, as the stock shows a month return of about 1.5% and a past 3 months return near 9.7%. See our latest analysis for Vertex Pharmaceuticals. At a share price of US$470.87, Vertex’s recent 90 day share price return of 9.7% sits alongside a relatively flat 1 year total shareholder return of 0.19%. This hints that momentum has picked up more recently...",
      "url": "https://finnhub.io/api/news?id=12d5f730e508eba4a1ffa2d8756da0dba64c423e6a3f9e4e842dc629a5459e7e"
    }
  },
  {
    "ts": null,
    "headline": "Provident Dumps 490,000 MapleBear Shares Worth $18 Million",
    "summary": "Maplebear Inc. connects North American households with personal shoppers through its technology-driven grocery delivery platform.",
    "url": "https://finnhub.io/api/news?id=2fc5cc63cbac55f11470881ca2ae81440d6d4afa000e4475afb647a980eaf7df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770683203,
      "headline": "Provident Dumps 490,000 MapleBear Shares Worth $18 Million",
      "id": 138973881,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Maplebear Inc. connects North American households with personal shoppers through its technology-driven grocery delivery platform.",
      "url": "https://finnhub.io/api/news?id=2fc5cc63cbac55f11470881ca2ae81440d6d4afa000e4475afb647a980eaf7df"
    }
  }
]